{"filings":[{"id":1480516,"accession_number":"0001816590-26-000047","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2026-07-07T10:33:23+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Compass Pathways reports positive 26-week Phase 3 COMP006 data for COMP360 in TRD; NDA on track for Q4 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["39% of 25 mg arm achieved ≥25% MADRS reduction at Week 6, maintained through Week 26.","Retreatment in Part B enhanced benefit: nearly 30% of responders at Week 6 later achieved remission.","Safety profile generally well-tolerated; SAEs similar across arms (6.3% vs 5.7%).","Rolling NDA submission with FDA on track for Q4 2026; launch anticipated H1 2027 subject to approval and DEA rescheduling.","COMP006 enrolled 581 participants with highly chronic TRD (average depressive episode >3 years)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-07-07","daily_digest_url":"/daily/2026-07-07","daily_digest_rank":9},{"id":704636,"accession_number":"0001816590-26-000046","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2026-05-28T10:43:10+00:00","items":["5.07"],"status":"ready","headline":"COMPASS Pathways shareholders re-elect directors and approve auditor at 2026 AGM","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["All four director nominees (Justin Gover, Daphne Karydas, Kathleen Tregoning, Jeffrey Jonas) were elected with over 58.6 million votes in favor each.","PricewaterhouseCoopers UK re-appointed as statutory auditor with 58,755,739 for, 56,042 against.","Non-binding advisory say-on-pay for named executive officers approved with 58,291,006 for, 455,870 against.","Dr. Annalisa Jenkins' board term ended after the AGM; thanked for eight years of service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":49683,"accession_number":"0001816590-26-000043","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2026-05-13T10:30:53+00:00","items":["2.02","9.01"],"status":"ready","headline":"Q1 net income $91.2M on warrant gain; cash $466M; FDA grants COMP360 rolling NDA submission","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA granted Compass NDA rolling submission for COMP360 in TRD based on positive Phase 3 data; CNPV awarded.","Net income $91.2M ($0.71 basic EPS) vs net loss $17.9M in Q1 2025; non-cash warrant gain of $130.9M.","Cash $466.0M at Mar 31 2026 (from $149.6M at Dec 31 2025); debt $50.5M (from $31.6M).","R&D expenses $26.5M (down from $30.9M); G&A $16.4M (down from $18.7M).","Final NDA submission on track for Q4 2026; 26-week COMP006 data expected early Q3 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108976,"accession_number":"0001816590-26-000021","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Pathways 2025 net loss $287.9M; COMP360 NDA submission on track for Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 net loss $287.9M ($3.08/share), vs $155.1M in 2024; includes $122.6M non-cash loss on warrant liabilities.","Q4 2025 net loss $93.9M ($1.00/share), vs $43.3M in Q4 2024.","COMP360 in TRD: highly statistically significant Phase 3 results; FDA meeting to confirm rolling NDA submission, expected completion in Q4 2026.","Phase 2b/3 trial in PTSD initiated after FDA acceptance of IND.","Cash $149.6M at Dec 31, 2025; $150M Feb financing plus $200M warrant exercise extends cash runway into 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108975,"accession_number":"0001628280-26-009501","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Compass Pathways prices $150M public offering of ADSs and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds $150M from 17.5M ADSs at $8/ADS and 1.25M pre-funded warrants at $7.9999 each.","Underwriters granted 30-day option for up to 2.8125M additional ADSs.","Offering expected to close on Feb 20, 2026, subject to customary conditions.","Proceeds to fund COMP005/COMP006 Phase 3 trials, PTSD Phase 2b/3 trial, and commercial readiness.","Company, officers, and directors agreed to a 60-day lock-up on share sales."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108974,"accession_number":"0001816590-26-000007","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Compass Pathways: Phase 3 COMP006 meets primary endpoint; COMP360 25mg shows -3.8 point MADRS reduction (p<0.001)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["COMP006: Two 25mg doses vs 1mg showed -3.8 point MADRS reduction (p<0.001) at Week 6, meeting primary endpoint.","39% of COMP006 25mg arm achieved clinically meaningful reduction (≥25% MADRS) at Week 6.","COMP005 single dose previously showed -3.6 point difference (p<0.001); durable effect through Week 26 after 1-2 doses.","Safety profile: TEAEs mostly mild/moderate, resolving within 24h; SAE suicidal ideation <1% across both trials.","Company requested FDA meeting to discuss rolling NDA submission for COMP360 in treatment-resistant depression."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108973,"accession_number":"0001816590-26-000004","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"COMPASS Pathways secures $150M loan from Hercules Capital, $50M funded immediately","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $150M term loan facility with Hercules Capital; $50M drawn on Jan 5, 2026 (Tranche 1).","Proceeds repay ~$31.1M existing debt; remaining funds for general corporate purposes.","Interest rate of 9.75% or prime+2.75%; interest-only payments until Q1 2029, maturity Jan 5, 2031.","Additional tranches up to $100M available upon clinical, FDA approval, and commercial milestones.","Loan secured by personal property (excluding IP); prepayment penalties from 0.5% to 2.0%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125429,"accession_number":"0001816590-25-000149","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Pathways accelerates COMP360 TRD launch by 9-12 months; Q3 net loss $137.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Accelerating commercialization readiness by 9-12 months after positive FDA meeting on NDA strategy including potential rolling submission.","COMP006 9-week data and COMP005 26-week data expected Q1 2026; COMP006 26-week data expected early Q3 2026.","Cash $185.9M as of Sept 30, 2025; full-year 2025 net cash used in operations expected $120M-$145M.","Q3 2025 net loss $137.7M ($1.44/share) includes $101.3M non-cash loss on warrant fair value adjustment.","R&D expenses $27.3M in Q3 2025 vs $32.9M in Q3 2024, down due to discontinued discovery programs."],"consensus_eps_estimate":-0.3978,"consensus_eps_actual":-2.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125428,"accession_number":"0001816590-25-000141","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Compass Pathways appoints Dr. Jeffrey Jonas to board; Thomas Lönngren to retire Dec 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Jonas appointed Board effective Oct 29, 2025; Class II director, audit and scientific committees.","Initial option for 52,000 ordinary shares vesting over 3 yrs; annual retainers $40k board, $10k audit, $6k scientific.","Thomas Lönngren to retire Dec 31, 2025 after 6+ years; no disagreements.","Dr. Jonas brings 30+ yrs neuroscience leadership; former CEO of Sage Therapeutics, partner at Cure Ventures.","Changes align with advancing COMP360 program and potential commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142164,"accession_number":"0001816590-25-000103","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Pathways reports Q2 2025 net loss $38.4M; COMP360 Phase 3 trial hits primary endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive Phase 3 COMP005 trial: primary endpoint met with high statistical significance and clinically meaningful reduction in depression symptoms at 6 weeks for COMP360 in TRD.","Second pivotal Phase 3 (COMP006) enrolling well; 26-week data expected H2 2026.","Exploring accelerated filing pathway for COMP360 in TRD; DSMB found no safety concerns in Phase 3 studies.","Net loss $38.4M (Q2 2025) vs $38.1M (Q2 2024); net loss per share $0.41 vs $0.56.","Cash $221.9M at June 30, 2025; cash runway into 2027; FY2025 net cash used in ops guidance $120-145M."],"consensus_eps_estimate":-0.4366,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142163,"accession_number":"0001816590-25-000094","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Compass Pathways appoints Justin Gover to board; Dr. Linda McGoldrick to retire Oct 31","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Justin Gover appointed as Class III director effective July 29, 2025; joins audit/risk and scientific committees.","Gover receives initial option for 52,000 ordinary shares vesting over 3 years; annual retainer of $40,000 plus committee fees.","Linda McGoldrick to retire from board effective October 31, 2025; no disagreement with company.","Gover was founding CEO of GW Pharmaceuticals (sold to Jazz for $7B) and led Epidiolex development/commercialization.","Currently also serves on Xenon Pharmaceuticals (XENE) board; brings 25+ years biopharma experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160159,"accession_number":"0001816590-25-000085","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Compass Pathways positive Phase 3 COMP005 psilocybin trial meets primary endpoint for TRD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["COMP360 25 mg single dose showed MADRS reduction -3.6 vs placebo (p<0.001) at week 6.","DSMB chair: no new safety findings; no clinically meaningful imbalance in suicidality.","258 participants enrolled across 32 US sites; blinded extension to week 26, open-label to 52.","COMP006 (568 participants) 26-week data expected H2 2026; company plans FDA discussions.","First pivotal Phase 3 positive; supports regulatory path for COMP360 in treatment-resistant depression."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160158,"accession_number":"0001816590-25-000067","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"COMPASS Pathways shareholders approve all 12 proposals at 2025 AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected directors Lönngren, McQuade, Nath, Santini with >44M votes each, ~30M broker non-votes.","Re-appointed PwC UK as statutory auditor and PwC US as independent auditor for FY2025.","Advisory say-on-pay and directors' remuneration report approved with ~40M for, ~4.5M against.","Authorized directors to allot shares up to £1,114,200 nominal value and disapplied pre-emption rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160157,"accession_number":"0001628280-25-023427","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Pathways Q1 net loss $17.9M; cash $260.1M; phase 3 top-line data expected late June","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.9M ($0.24 diluted EPS) vs $35.2M ($0.55) in Q1 2024; includes $19.5M non-cash gain on warrant liabilities.","R&D expenses $30.9M, up 24% YoY due to advancing COMP360 phase 3 trials; G&A $18.7M, up 36%.","Cash $260.1M at Mar 31, 2025, vs $165.1M at Dec 31, 2024; net cash raised $140.4M in Q1.","Top-line 6-week data from COMP005 phase 3 in TRD expected late June 2025; COMP006 26-week data H2 2026.","Full-year 2025 net cash used in ops guided at $120M-$145M; cash expected to fund through COMP006 readout."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160156,"accession_number":"0001816590-25-000042","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["4.01","5.02","9.01"],"status":"ready","headline":"Compass Pathways replaces PwC UK with PwC US as auditor; NEOs get change-in-control vesting acceleration","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["PwC UK resigned at company's request; PwC US appointed independent auditor for FY2025 effective after Q1 2025 review.","No disagreements or reportable events with PwC UK for fiscal years 2024 and 2023.","Change driven by Compass Pathways' status as US domestic reporting company and growing US operations.","Employment agreements amended: full accelerated vesting of time-based equity awards if NEO terminated or resigns for good reason within 12 months post-change in control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178470,"accession_number":"0001628280-25-008414","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Pathways reports FY2024 net loss of $155.1M; Phase 3 data on track for Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2024 was $155.1M ($2.30 loss per share) vs $118.5M ($2.32 loss per share) in FY2023.","Cash and cash equivalents $165.1M at Dec 31, 2024; additional $140.4M net raised in Q1 2025.","Phase 3 COMP005 top-line 6-week data for TRD on track for Q2 2025; COMP006 26-week data expected H2 2026.","R&D expenses rose to $119.0M from $87.5M, driven by phase 3 trials and strategic reorganization costs.","Steve Levine, M.D., appointed Chief Patient Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178469,"accession_number":"0001816590-25-000008","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Compass Pathways prices $150M offering of ADS and warrants to fund Phase 3 depression/PTSD trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 24.0M ADS and 11.0M pre-funded warrants plus accompanying ADS warrants at $4.275/unit (ADS warrant strike $5.796).","Gross proceeds ~$150M; up to ~$353M if ADS warrants fully exercised; led by Deep Track Capital.","Net proceeds fund ongoing COMP005/COMP006 Phase 3 depression trials (data Q2 2025, H2 2026) and accelerate PTSD program.","Company terminates ATM sales agreement (up to $93.5M capacity) effective January 9, 2025.","Offering expected to close January 13, 2025; 60-day lock-up for officers/directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195143,"accession_number":"0001628280-24-044400","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Pathways delays COMP360 phase 3 data to Q2 2025; workforce reduction of 30%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["COMP005 phase 3 top-line data in TRD now expected Q2 2025; COMP006 data shifted to H2 2026 after unblinding risk.","Workforce reduction of ~30% including senior management roles; non-COMP360 preclinical halted; digital health tools explored for externalization.","Net loss Q3 2024 $38.5M ($0.56 loss per share) vs $33.4M loss ($0.67 loss per share) in Q3 2023.","Cash and equivalents $207M as of Sept 30, 2024; projected to fund operations at least into 2026.","R&D expenses rose to $32.9M in Q3 2024 from $21.5M in Q3 2023, driven by phase 3 clinical costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211406,"accession_number":"0001628280-24-033854","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Compass Pathways Q2 net loss $38.1M; COMP005 phase 3 TRD data expected Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $38.1M ($0.56 per share) vs $28.3M in Q2 2023; R&D expenses rose to $29.1M.","Cash position $228.6M as of June 30, 2024; full-year 2024 operating cash burn guided $110M-$130M.","Top-line COMP005 pivotal phase 3 data in treatment-resistant depression expected Q4 2024.","Gino Santini appointed Chairman of Board effective September 3, 2024; Lori Englebert named CCO.","Phase 2 PTSD study showed sustained symptom improvement; exploring optimal path forward."],"consensus_eps_estimate":null,"consensus_eps_actual":-1110.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230044,"accession_number":"0001816590-24-000086","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"Compass Pathways holds AGM; all 12 proposals pass; auditor consent corrected","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 12 proposals at May 9, 2024 AGM passed, including director elections and auditor ratification.","Directors re-elected: David Norton, Wayne J. Riley, and Daphne Karydas.","PricewaterhouseCoopers LLP re-appointed as UK statutory auditor and ratified as independent auditor for FY2024.","Advisory votes on executive compensation, directors' remuneration report, and remuneration policy approved.","Revised auditor consent filed to correct omission of a registration statement in prior 10-K; no financial impact."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230043,"accession_number":"0001816590-24-000083","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Compass Pathways reports positive Ph2 data for COMP360 psilocybin in PTSD; meets safety endpoint","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 open-label study of 22 PTSD patients; single 25mg dose plus psychological support met primary safety endpoint.","No serious adverse events; common AEs mild: headache (50%), nausea (36.4%), crying (27.3%), fatigue (27.3%).","Mean CAPS-5 total score reduced 29.9 points at week 4 and 29.5 points at week 12 from baseline of 47.5.","Response rate (≥15-point CAPS-5 improvement) 81.8% at week 4 and 77.3% at week 12; remission rate 63.6% at week 4.","No patient withdrawals and no return to antidepressant medication during the 12-week study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230042,"accession_number":"0001628280-24-021352","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Pathways Q1 net loss $35.2M ($0.55/share); phase 3 TRD on track; PTSD phase 2 positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $35.2M vs $24.2M in Q1 2023; EPS loss $0.55 vs $0.57.","Cash $262.9M at March 31, 2024, up from $220.2M; net $63.5M raised via ATM and warrants.","COMP360 phase 3 for TRD on track: COMP005 top-line Q4 2024, COMP006 mid-2025.","Phase 2 PTSD open-label: 25mg single dose well tolerated; CAPS-5 reduction 29.9 pts at week 4.","Michael Gold joins as Chief R&D Officer May 20; Trevor Mill departs as Chief Development Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.55,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248485,"accession_number":"0001628280-24-013452","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2024-03-28T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Compass Pathways co-founders George Goldsmith and Ekaterina Malievskaia resign from board; David Norton interim chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Resignations effective March 29, 2024; not due to any disagreement with company.","David Norton, former lead independent director, becomes interim board chair.","Company initiates global search for permanent chair with biotech and strategic experience.","Norton is a former Johnson & Johnson Company Group Chairman for Global Pharmaceuticals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248484,"accession_number":"0001628280-24-007788","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Compass Pathways Q4 2023 net loss $32.5M; COMP005 data delayed to Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2023 $118.5M ($2.32/sh) vs $91.5M ($2.16/sh) in 2022.","Cash $220.2M at Dec 31, 2023; raised additional $31.4M net in Q1 2024.","COMP005 phase 3 top-line data delayed to Q4 2024; COMP006 still on track for mid-2025.","Teri Loxam appointed CFO effective March 1, 2024.","FY2024 net cash used in operations expected $110-130M; runway into late 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265984,"accession_number":"0001816590-23-000142","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Compass Pathways appoints Teri Loxam as CFO effective March 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Teri Loxam appointed CFO effective March 1, 2024 or filing of 2023 annual report; advisory role until then.","Compensation: base salary $490,000, target bonus 45%, initial equity awards totaling $1.8M (60% options, 40% RSUs).","Loxam has >20 years pharma/biotech experience, including CFO at Gameto, Kira, SQZ Biotech; senior IR at Merck, BMS, IMAX.","Mary-Rose Hughes continues as interim CFO until Effective Date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265983,"accession_number":"0001628280-23-036181","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"COMPASS Pathways Q3 net loss $33.4M; COMP360 Phase 3 on track; cash $248M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $33.4M ($0.67/share) for Q3 2023 vs $18.4M ($0.43) YoY; R&D expenses rose to $21.5M.","Cash and equivalents $248.0M at Sept 30, 2023; raised $125M upfront from private placement with up to $160M more if warrants exercised.","Phase 3 COMP005 top-line data expected summer 2024; COMP006 top-line expected mid-2025; Phase 2 PTSD data by end of 2023.","Full-year 2023 net cash burn guidance lowered to $79M-$85M; Q4 expected $9M-$15M.","Mike Falvey departed; Mary-Rose Hughes named interim CFO; search for permanent CFO underway."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265982,"accession_number":"0001816590-23-000131","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"COMPASS Pathways CFO Mike Falvey departs; Mary-Rose Hughes named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Michael Falvey resigns effective Oct 26; will advise through Nov 3 to pursue other opportunities.","Separation agreement includes $638,000 payment (12 months salary + bonus) and 25% equity acceleration.","Interim CFO Mary-Rose Hughes (VP Finance since May 2020) appointed; base salary raised 30% plus £30k bonus.","Company has initiated a search for a permanent chief financial officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283211,"accession_number":"0001816590-23-000123","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2023-09-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"COMPASS Pathways appoints Daphne Karydas to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective September 18, 2023; Karydas is President/CFO of Flare Therapeutics.","Received initial option for 52,000 ordinary shares (or ADSs) vesting over three years.","Annual cash retainers: $40,000 as director, $8,000 as audit/risk committee member.","Serves as Class III director; brings over 20 years biopharma financial and strategy experience.","No family relationships with directors/officers; no material transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283210,"accession_number":"0001816590-23-000104","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2023-08-16T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"COMPASS Pathways raises $125M upfront in private placement; warrants could add $160M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 16.08M ADSs and warrants to purchase 16.08M ADSs at $7.78 per unit; warrant strike $9.93 (30% premium).","Transaction led by TCGX and Aisling Capital with participation from Vivo Capital, RA Capital, and others.","Net proceeds expected to extend cash runway into late 2025; funds Phase 3 TRD program and other trials.","Closing expected August 18, 2023; registration statement for resale to be filed within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283209,"accession_number":"0001628280-23-026987","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"COMPASS Pathways H1 2023 net loss $52.5M; Phase 3 psilocybin trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for H1 2023: $52.5M ($1.19 loss per share) vs $42.2M ($1.00) in H1 2022.","Cash $148.2M; secured $50M term loan from Hercules Capital, $28.1M drawn.","COMP360 Phase 3 TRD trials on track; topline data expected summer 2024 (COMP 005) and mid-2025 (COMP 006).","AMA accepted CPT III code for in-person psychedelic therapy support, aligning with COMP360 requirements.","ATAI exercised demand registration rights for 7,935,663 shares; filing required within 45 days."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283208,"accession_number":"0001816590-23-000093","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Compass Pathways secures up to $50M term loan from Hercules Capital, draws $30M initially","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan facility up to $50M; initial $30M drawn on June 30, 2023; two additional tranches of $10M each available subject to milestones and lender approval.","Interest at greater of 9.75% or prime+1.5%; interest-only until July 2025 (or extended to July 2026 if milestones met); matures July 2027.","Proceeds to fund COMP360 phase 3 trial in treatment-resistant depression; initial data expected summer 2024.","Warrant issued to Hercules for 94,222 shares at $7.96 per share (10-year term), representing 2.5% of principal.","Loan secured by assets but excludes IP; includes financial covenant to maintain qualified cash after Jan 1, 2024; prepayment penalties apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302623,"accession_number":"0001816590-23-000074","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Compass Pathways shareholders re-elect all directors, approve auditor and compensation at 2023 AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders re-elected directors George Goldsmith, Annalisa Jenkins, Linda McGoldrick, and Kabir Nath.","Re-appointed PricewaterhouseCoopers LLP as UK statutory auditor and ratified as independent accounting firm for FY 2023.","Advisory vote approved directors' remuneration report and named executive officer compensation for 2022.","All 10 proposals passed; broker non-votes totaled 20,917,244 on each item due to ADS holders without instructions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302622,"accession_number":"0001816590-23-000072","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2023-05-31T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"COMPASS Pathways co-founder Ekaterina Malievskaia steps down as Chief Innovation Officer, remains on board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Malievskaia will step down as Chief Innovation Officer effective June 16, 2023, by mutual agreement.","She will remain a non-executive director, Class I, with term expiring at 2024 annual meeting.","Executive responsibilities will be assumed by the existing executive team.","She co-founded COMPASS in 2017 and led the phase 2b trial of COMP360 psilocybin for treatment-resistant depression.","Transitioning to non-executive director, she will receive annual cash retainer of $40,000 and equity awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302621,"accession_number":"0001628280-23-017392","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"COMPASS Pathways Q1 net loss $24.2M ($0.57/sh); Phase 3 psilocybin trials underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.2M ($0.57 loss per share) vs $21.2M ($0.50) in Q1 2022.","Cash $117.1M at March 31, 2023; raised additional $26.9M net via ATM in Q2.","Phase 3 pivotal trials (COMP 005, COMP 006) in TRD underway; top-line data expected summer 2024 and mid-2025.","CPT III code for psychedelic therapy support accepted by AMA, effective Jan 1, 2024.","FY 2023 net cash used in operating activities guidance $85M-$110M; Q2 guidance $22M-$30M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302620,"accession_number":"0001816590-23-000053","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2023-04-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"COMPASS Pathways furnishes updated corporate presentation; no material details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Updated corporate presentation made available on website and for investor meetings beginning April 19, 2023.","Presentation content from filing exhibit is limited to title slide only; no specific financial or clinical data provided.","Company disclaims any obligation to update the material; presentation is current as of April 19, 2023.","Filing is under Regulation FD; information is furnished, not filed, and not incorporated by reference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322282,"accession_number":"0001628280-23-005357","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2023-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"COMPASS Pathways reports FY2022 net loss of $91.5M; Phase 3 psilocybin trials underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2022 was $91.5M ($2.16 loss per share) vs $71.7M ($1.79 loss per share) in 2021.","Cash and cash equivalents fell to $143.2M at Dec 31, 2022 from $273.2M a year earlier.","Phase 3 pivotal program for COMP360 psilocybin in TRD ongoing; top-line data from trial COMP 005 expected summer 2024.","R&D expenses increased to $65.1M in FY2022 from $44.0M in FY2021, driven by clinical development.","FY2023 net cash used in operating activities guided at $85M-$110M; Q1 2023 at $24M-$32M."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322281,"accession_number":"0001816590-23-000004","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2023-01-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Compass Pathways furnishes updated corporate presentation; no specific data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated Jan. 6, 2023, intended for use at J.P. Morgan Healthcare Conference.","No material non-public financial or operational data disclosed in the filing.","Company disclaims obligation to update the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":340324,"accession_number":"0001816590-22-000117","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"COMPASS Pathways: Q3 net loss $18.4M ($0.43/share); Phase 3 program on track for 2022 start","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.4M in Q3 2022 vs. $15.8M in Q3 2021; cash $173.1M as of Sept 30, 2022.","Phase 3 pivotal program for COMP360 in treatment-resistant depression on track to start in 2022.","Phase 2b trial data published in The New England Journal of Medicine.","Phase 2 trials ongoing in anorexia nervosa and PTSD; investigator-led study in autism launched."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357591,"accession_number":"0001628280-22-020850","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"COMPASS Pathways reports Q2 net loss of $21.0M, appoints Kabir Nath as CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q2 2022 was $21.0M ($0.50 loss per share) vs $17.5M ($0.44) in Q2 2021.","Cash and cash equivalents of $207.2M at June 30, 2022, down from $273.2M at Dec 31, 2021.","Kabir Nath appointed CEO; George Goldsmith remains Executive Chairman through Dec 2022.","Phase 3 protocols for COMP360 in TRD submitted to FDA, under review; Phase 3 start expected Q4 2022.","Phase 2 study of COMP360 in anorexia nervosa launched across four research sites in the UK and US."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357590,"accession_number":"0001816590-22-000073","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2022-07-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"COMPASS Pathways appoints Kabir Nath as CEO effective August 1, 2022; George Goldsmith becomes Executive Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kabir Nath appointed CEO, effective August 1, 2022; he brings 30 years biopharma experience, most recently at Otsuka and Bristol-Myers Squibb.","George Goldsmith transitions to Executive Chairman from Aug 1 to Dec 31, 2022, then remains Chairman; his base salary is £346,800 with 55% target bonus.","Nath receives $580,000 base salary, 60% target bonus, 600,000 stock options and 50,000 RSUs vesting over four years.","Nath also gets a £12,000/month housing stipend through Aug 2023, $5,000 legal fees, and $250,000 relocation payment.","Goldsmith's pro-rated 2022 bonus reflects reduced salary from August; employment ends Dec 31, 2022 per amended agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376191,"accession_number":"0001816590-22-000066","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2022-06-24T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"PTAB denies post-grant review of two Compass Pathways patents","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Patent Trial & Appeal Board denied institution of post-grant review for US patents 10,947,257 and 10,954,259 on June 22, 2022.","Freedom to Operate had filed petitions challenging patentability on three grounds: improper subject matter, obviousness, and lack of enablement.","Decision upholds validity of key patents covering COMPASS's psilocybin-related intellectual property.","Outcome removes near-term patent invalidation risk for Compass Pathways."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376190,"accession_number":"0001816590-22-000055","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Compass Pathways reports 2022 AGM voting results; all proposals approved, director Camm departs","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine proposals passed: re-elected directors Lönngren and McQuade, ratified PwC as auditor, and approved say-on-pay.","Non-binding advisory say-on-pay received 20,382,371 for vs. 59,005 against; frequency set to annual with 20.6M votes for 1 year.","Jason Camm did not stand for re-election; his board term ended at the AGM as previously disclosed.","Total shares represented: 23,460,763; broker non-votes of 19,026,749 on most proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376189,"accession_number":"0001628280-22-013441","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"COMPASS Pathways reports Q1 2022 net loss of $21.2M; cash $243.7M; FDA end-of-phase II meeting held","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.2M ($0.50/sh) vs $12.7M ($0.35) in Q1 2021; R&D expenses $15.4M (up from $6.9M).","Cash and cash equivalents $243.7M as of March 31, 2022, down from $273.2M at Dec 31, 2021.","End-of-phase II meeting with FDA completed; finalizing Phase III design for TRD program targeting H2 2022.","Awarded Innovation Passport under UK MHRA ILAP for COMP360 psilocybin therapy.","Phase II trial in PTSD ongoing; collaboration with King's College London and NHS for mental health research."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":376188,"accession_number":"0001816590-22-000031","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2022-04-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Jason Camm to leave COMPASS Pathways board at 2022 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jason Camm will not stand for re-election at annual general meeting around June 16, 2022.","Camm will continue as director until term expires at the meeting, then step down.","He also retires from Compensation and Leadership Development and Nominating and Corporate Governance Committees.","Departure not result of any disagreement with the Company on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394543,"accession_number":"0001816590-22-000014","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2022-03-25T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"COMPASS Pathways establishes The Centre for Mental Health Research and Innovation with King's College London and SLaM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to £12M investment over 10-year term; Centre to accelerate psychedelic therapy research and new care models.","Initial focus on COMP360 psilocybin therapy for TRD, PTSD, and anorexia nervosa; expects 650-700 patients over 5 years.","Facilities to be built at Bethlem Royal Hospital in London; state-of-the-art clinical trial space.","Partnership with UK's largest NHS mental health trust (SLaM) and King's College London's IoPPN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394542,"accession_number":"0001628280-22-003658","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"COMPASS Pathways reports FY2021 net loss $71.7M; positive phase IIb TRD results, FDA meeting in April","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2021 was $71.7M ($1.79 loss per share), vs $60.3M in FY2020; Q4 net loss $25.7M.","Cash balance $273.2M at year-end 2021, up from $190.3M in 2020; well-capitalized for phase III.","Positive phase IIb trial of COMP360 psilocybin for TRD: rapid and sustained response at 25mg dose.","End-of-phase II meeting with FDA scheduled for late April 2022; phase III expected H2 2022.","New senior executives: Dr Guy Goodwin (CMO), Mike Falvey (CFO), Matt Owens (General Counsel)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394541,"accession_number":"0001816590-22-000008","cik":1816590,"company_name":"COMPASS Pathways plc","ticker":"CMPS","form_type":"8-K","filed_at":"2022-02-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Compass grants equity awards to CEO Goldsmith (173k options, 29k RSUs) and Malievskaia (75k options, 13k RSUs)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO George Goldsmith received 173,000 options and 29,000 RSUs.","Ekaterina Malievskaia received 75,000 options and 13,000 RSUs.","Options vest monthly over 48 months; RSUs vest annually over 4 years.","Awards granted under the 2020 Share Option and Incentive Plan effective Feb 1, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1598841097.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}